Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316628 | 1.00 | GSR (0.52) | GSRNOS3NOS1NOS2ITGB3 | |
| Hydrochloric Acid SCHEMBL21332553 | 0.98 | NOS3 (0.50) | GSRNOS3NOS1NOS2ITGB3 | |
| Hydrochloric Acid SCHEMBL21332552 | 0.98 | NOS3 (0.50) | GSRNOS3NOS1NOS2ITGB3 | |
| SCHEMBL525228 | 0.87 | NOS3 (0.55) | GSRNOS3NOS1NOS2ITGB3 | |
| SCHEMBL479185 | 0.87 | NOS3 (0.55) | GSRNOS3NOS1NOS2ITGB3 | |
| SCHEMBL31688706 | 0.87 | NOS3 (0.55) | GSRNOS3NOS1NOS2ITGB3 | |
| SCHEMBL31688521 | 0.86 | NOS3 (0.50) | GSRNOS3NOS1NOS2ITGB3 | |
| Hydrochloric Acid SCHEMBL524956 | 0.85 | NOS3 (0.53) | GSRNOS3NOS1NOS2ITGB3 | |
| Hydrochloric Acid SCHEMBL524957 | 0.85 | NOS3 (0.53) | GSRNOS3NOS1NOS2ITGB3 | |
| Hydrochloric Acid SCHEMBL6873225 | 0.85 | NOS3 (0.53) | GSRNOS3NOS1NOS2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3761985-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University - Of The Commonwealth System of Higher Education (US) | 2021-01-13 | — | — | EP | claimed |
| CN-112105364-A | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2020-12-18 | — | — | CN | claimed |
| US-20200392075-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2020-12-17 | — | — | US | claimed |
| WO-2019173633-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-09-12 | — | — | WO | claimed |
| EP-3761985-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University - Of The Commonwealth System of Higher Education (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-112105364-A | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2020-12-18 | — | — | CN | disclosed |
| US-20200392075-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2019173633-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-09-12 | — | — | WO | disclosed |
| CN-101868476-B | Glucagon-like peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK AS | 2015-02-25 | — | — | CN | disclosed |
| CN-101842109-B | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK AS | 2014-01-29 | — | — | CN | disclosed |
| CN-102905722-A | Long-acting Y2 receptor agonists | NOVO NORDISK AS | 2013-01-30 | — | — | CN | disclosed |
| CN-102573888-A | Long acting Y2 receptor agonists | NOVO NORDISK AS | 2012-07-11 | — | — | CN | disclosed |
| EP-0775160-A1 | CYCLIC HEXAPEPTIDE SOMATOSTATIN ANALOGUES | DIATECH, INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5620675-A | MEDICAL DIAGNOSIS | DIATECH, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0720621-A1 | RADIOLABELED SOMATOSTATIN-DERIVED PEPTIDES FOR IMAGING AND THERAPEUTIC USES | Diatide, Inc. (US) | 1996-07-10 | — | — | EP | disclosed |
| WO-1996004308-A1 | CYCLIC HEXAPEPTIDE SOMATOSTATIN ANALOGUES | DIATECH, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0649434-A1 | RADIOACTIVELY-LABELED SOMATOSTATIN-DERIVED PEPTIDES FOR IMAGING AND THERAPEUTIC USES | Diatide, Inc. (US) | 1995-04-26 | — | — | EP | disclosed |
| WO-1995003330-A1 | SOMATOSTATIN DERIVATIVES AND THEIR RADIOLABELLED PRODUCTS | DIATECH, INC. (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995000553-A1 | RADIOLABELED SOMATOSTATIN-DERIVED PEPTIDES FOR IMAGING AND THERAPEUTIC USES | DIATECH, INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994000489-A2 | RADIOACTIVELY-LABELED SOMATOSTANTIN-DERIVED PEPTIDES FOR IMAGING AND THERAPEUTIC USES | DIATECH, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392075-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, NR1H3, NR1H2 | GSR 208/4885NOS3 1314/4885NOS1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.